Callouts & quotes from 10,384+ activist slides

""...we’re not at all surprised that value-oriented investors have taken a significant stake... with Box spending ~41% of revenue on sales and marketing (higher than most SaaS peers in the ~30% range), we think a shift towards margin expansion could provide an avenue for unlocking shareholder value." — Raymond James, September 2019; "Margin profile is unfit for BOX’s current growth rate. With S&M at north of 40% of revenue, we should be seeing a greater impact in revenue and billings acceleration. Gross margin also continues to decline, coming in at 71.3% this quarter, in comparison to 72.3% last quarter." — Craig-Hallum, August 2019"

""There's a lot of headwinds for an enterprise-only focused block storage provider...The enterprise block market is static... it's not growing nearly as fast as the unstructured data market." — Executive at VAST Data and former Pure employee; "It's somewhat mainstream to take software and run it on whatever conventional server platform they already have. So that flexibility doesn't exist with Pure" — Executive at DDN and former Pure employee; "For the small to mid-size enterprises, they're not necessarily clamoring for 128 terabytes in one drive. They can do just fine with less capacity" — Marketing executive at SSD supplier Solidigm"

"Do you think that maybe because your sort of the one big dominant player in the industry, you're a little bit more insulated from maybe competitor discounts and promotions, maybe relative to some other apparel footwear companies out there? — Analyst. That said, you're right to call out that we are the brand in the industry. We're the leading brand in the industry, and we really almost never turn up the promotional lever because it just doesn't seem to pay back either in that year and certainly not in the following year when we have to go off again, sort of an artificial lift in sales that may have been margin eroding. — CEO Response"

"“We would never allow bulk orders, ever, under any circumstance, given the sensitivity of the pricing... I’m closing out the quarter and my average sale price to you is $27,000, but if you order 25 for next quarter, I’ll knock it down to $22,000-$23,000.” — Nevro ex-executive; “The ongoing problem that Nevro has is that once doctors start paying $2,3,4 thousand dollars less per device they say ‘Well, I don’t want to go back to the high price’ and of course an Abbott will match that price because it’s new business for them. It was a stupid move. Fundamentally, it was one of the dumbest moves you could ever make.” — Nevro ex-executive"

"“if that get’s revealed, if that gets exposed in any way, that’s curtains...I have known of some sites in our region that would get these kinds of calls...other regions...this kind of hotline for organs that were turned down...this kind of workaround...it allowed them consequently to boost their numbers substantially in a given year with these organs...we scratch our heads wondering how in the heck did these guys get these organs? How did that happen? That’s not what ought to be happening through our new allocation system...there’s a lot of game playing going on out there.” — Transplant hepatologist at Massachusetts General Hospital"

"Q - Keith Howlett: "On Note 5 [of the FY 2013 Annual Report], I was trying to figure out the leasehold improvements, there seemed to be some items called 'disposals at cost,' and there's sort of an offset there." A - Larry Rossy, CEO: "I don't know what guys, you're going to have to help me out, guys, here." A - Michael Ross, CFO: "Disposal of costs, that would be fixtures or related to..." A - Rossy: "I would say cars." A - Ross: "Cars. Yeah, okay. We sold a few cars." Q - Howlett: "Oh, I see, okay. Well, it shows up as CAD 15M for a year, that's a lot of cars." A - Rossy: "Oh, it's a very expensive car." — FY 2013 Q4 Earnings Call"

""The complexity of Sony's business structure, which ranges from video game platforms to cutting-edge semiconductors and life insurance...appears to have discouraged entry by a broad range of investors. If investors were to invest in Sony in order to profit from earnings growth driven by the shift to digital distribution in the game and network services business, the firm's largest business, they would also need to accept risks arising from competitive conditions in the semiconductor business and restructuring in the mobile communications business since games account for less than 40% of total earnings." — Goldman Sachs, October 2018"

""of course...that’s probably what it will come to...I think that’s what it’s going to come to." — Endocrinologist #3; "kids like drinking liquids" — Endocrinologist #3; "if there’s an equation, we’ll find it." — Endocrinologist #3; "If it's on MDCalc, I think we'll feel good about it" — Endocrinologist #3; "MDCalc is this website where you can do some calculations, like corrected calcium levels, fractional excretion...steroid conversions. So, if we're able to have that resource for the suspension versus the tablet, interchanging the dosages, I think that's going to help the docs a lot for prescribing off-label." — Endocrinologist #3"

"Two years ago, the Nashville Vought Aircraft Industries plant was scheduled to be shut down to streamline costs. Instead, the 1,200 jobs stayed in Nashville, the company became profitable and productivity, safety and morale improved steadily. At the helm is Vought CEO and President Elmer Doty, who brought in new management and led a strategic planning effort at the aerospace industry manufacturer. Doty and his new management crew - 40 percent of whom were from outside the aerospace industry - scrutinized everything from low morale to aging facilities and equipment to supply chain problems. — Nashville Business Journal, May 11, 2008"

""We believe that having an independent chair is the preferred structure for board leadership. Having an independent chair avoids the inherent conflict of self-oversight and helps ensure robust debate and diversity of thought in the boardroom." — Wellington; "The roles of chair and CEO are substantially different, requiring distinctly different skills and experience. Therefore, LGIM expects the two roles to be separated." — Legal & General; "Harris has an existing guideline that states that we will normally vote in favor of proposals requiring the separation of the Chairman and Chief Executive Officer positions" — Harris Associates."

"“I went up against Twist many times as a sales rep. For the customers that cared most about things like turnaround time, reliability, low mutation rates of dsDNA or many other metrics that are quantitative. Those customers, I think Twist had a hard time grabbing. But the more price-sensitive and/or the ones that didn't care as much for one reason or another, depending on what research you're doing, you might not need the most accurate DNA in the world, like it might not matter to what you're doing. Twist would win. I lost to them many, many times as a competitor. That's my experience.” — IDT ex-regional sales manager, left recently"

"On January 15, 2011 Nautilus Minerals acquired the shares necessary to hold a 100% interest in United Nickel Inc and simultaneously disposed of United Nickel's interest in Nauru Offshore Resources Limited (which was a wholly owned subsidiary of United Nickel). United Nickel, (currently 0813631 B.C. Ltd) is to be renamed, and through its wholly owned subsidiary Tonga Offshore Mining Limited, has an application pending with the International Seabed Authority to obtain a licence to explore for polymetallic nodules on the seafloor in the international seabed area covering approximately 74.713 square kilometres. — NMI 2010 Annual Report"

"“This was all nebulous because pain management and neuromodulation are subjective. The primary endpoint in the Nevro trials was VAS reductions. The problem is it’s very subjective. Patients’ pain and location can change hour to hour and day to day. It’s such a tough specialty because it’s so nebulous. If the diagnosis is an ACL tear, the surgeon can confirm it with imaging. The problem with chronic pain is that it’s not one specific modality. There’s a major psychological component, which is why a psychiatric evaluation is required for permanent implant.” — Former Nevro regional sales director, head of a large multi-state territory"

"“Well, I would and I'd be very happy to. I do off-label and generic prescribing all the time for things like ketoconazole for my patients with advanced Cushing's...I predict that I can achieve similar plasma levels and clinical efficacy with both an oral formulation and at low cost, even if it requires off-label prescribing. I'm totally in. That is an easy win for me, and I'm super happy to prescribe it both off-label and in this different oral formulation if it works as well...I will for sure take that approach rather than prescribing an outrageously priced drug.” — Endocrinologist with academic and community hospital affiliations"

"“As Rick said, we do sort of the ground game for us is those smaller acquisitions that we do roughly one a quarter and we consider that more like an organic activity.” — CFO Mike Sicoli, Q2 2018 earnings call; “We add these smaller acquisitions and buying books of business which I call organic as well because it's a lot less expensive sometimes to buy those books than to take six months or nine months to build a sales organization to achieve that.” — Executive Chairman H. Brian Thompson, Q4 2017 earnings call; “The organic part of our business is also the combination of small acquisitions.” — CEO Rick Calder, Q3 2018 earnings call"

""But the market wages are shifting on us literally every single month. So we have to be aware that we will see wages go up next year. We have the ability to pass on some, but not all of that to our customers. The majority of our contracts on an account basis have cost-of-living adjustments baked into them, where we can increase customers' rates commensurate with the wage increase that we're going to give to our employees. But some of our largest contracts, which are signed for 2-year or 3-year terms, have fixed pricing. And so in some cases, we'll see a gross margin impact as a result of that." — CEO Maddock, JPM Conf Nov 18, 2021"

"The CEO came from Chevron Phillips Chemical. That is another thing I think they should look at. Take Mark Lashier, he's an expert there, and spin off that business. — Anonymous Investor; We have had significant issues with Mark Lashier, who's the CEO. He is on the hot seat at this point due to these operational issues. — Anonymous Investor; This last Q4 where Phillips came out and their refining margins were so weak, so weak. That is just fundamentally unacceptable. — Anonymous Investor; Mark controls everything and that is not a good thing and as you can see that does not lead to strong corporate performance. — Anonymous Investor"

""We believe that having an independent chair is the preferred structure for board leadership. Having an independent chair avoids the inherent conflict of self-oversight and helps ensure robust debate and diversity of thought in the boardroom." — Wellington; "The roles of chair and CEO are substantially different, requiring distinctly different skills and experience. Therefore, LGIM expects the two roles to be separated." — Legal & General; "Harris has an existing guideline that states that we will normally vote in favor of proposals requiring the separation of the Chairman and Chief Executive Officer positions" — Harris Associates"

"Rubicon: "Our advertising spend, revenue, cash flow from operations, Adjusted EBITDA, operating results, and other key operating and financial measures may vary from quarter to quarter due to the seasonal nature of buyer spending. For example, many buyers devote a disproportionate amount of their advertising budgets to the fourth quarter of the calendar year to coincide with increased holiday purchasing." — Rubicon 10-K, p.14; Telaria: "During the first quarter, advertisers generally devote less of their budgets to ad spending, with the fourth quarter generally representing the largest quarter of ad spending." — Telaria 10-K, p.21"

"The consumer would never know any different. And like it was always kind of a weird thing were like, if you were the Flex agent in a given market, no one really wanted that word to get out. Like you would still show up in the pricing tool for other agents to see how much you were spending even if you weren't really spending that money because you're getting the Flex leads. So when they switch to Flex, they still left those agents in that tool to continue to drive competition but didn't tell anybody, hey, this guy is actually getting these leads on the Flex program, not on the MBP program. — Former Flex Account Executive At Zillow"

"“Yeah, that’s exactly right. I’ve seen that where it’s like we have a liver on pump - other OPO’s where they’ve called us and said we’re just moving quick, if we bypass the list, would you accept this liver?” — Transplant surgeon, Utah; “The agreement is if we have a rapid donor that may not have serologies, we may not have list run; we may not have certain things, TransMedics is willing to because they’re using it as storage, send out a team, put it on pump with no home and then offer it out, and they’ll accept the cost if they don’t because ultimately, most of the time, those organs will be accepted.” — Transplant surgeon, Utah"

"“there was not a huge difference in my patients...so really, what was the improvement?”; “all these drugs have a strong placebo effect...you could argue that it was placebo effect”; “placebo withdrawal which is unusual in terms of trials...an unusual study plan...that’s unusual.”; “the HQ-CT score, it’s not a great marker...it’s a subjective core...will vary depending on...whether it’s the mom, dad, or grandparents”; “the median score of 20, that’s a very high score...most of my patients are nowhere near that...is it just placebo effect goes down for the score from 23 down to 15...is that really the drug?” — Trial investigator #7"

"“They are metals, they are cations, they are positively charged metals. And I’ve been concerned about this in those with the type I deletion. And they account for about 1 of every 4 Prader-Willi patients... your blood becomes more sluggish, more prone to blood clots... Vykat is an ATP-sensitive potassium channel. Potassium, and those with the type I deletion will have a problem maintaining their potassium levels in their cells. And magnesium; it’s very key on magnesium. Magnesium is one of the important balancers that keeps us from not having seizures.” — Trial investigator and physician; one of the leading KOL’s in the PWS field"

""And we think that will be a very good economic roundtrip of invested capital on the part of APC into the MLP, and then reinvest that capital again. It really, for us, mid-stream delivers our upstream story. We're not trying to develop a separate midstream line of business that has a lot of third party work that will go into it, but rather it will be something that supplements what we would otherwise be doing for ourselves on balance sheet, by having a different access to capital and a different way to recognize the value of those assets in the market place." — Al Walker, Current CEO, Former SVP & CFO Anadarko (November 8, 2007)"

"“they cannot come up with these really long oligos”; “you only use that in the early, early stages of discovery which is mostly in academia, biotech, or in some labs in the pharma. You use them, you discover a gene or a pathway, and then you move forward and then you don’t use that technology anymore.”; “They do sell oligos longer than 250, but then they take much longer because they need to use another technology. So, this oligo pool that you explained, that they claim that they can do things so fast and so many at once, is for small oligos, and this is for library preparation for the CRISPR.” — Novartis, a large Twist customer"

"I'm hesitant to describe this...I would say there is an investigator that I felt just behaved very strangely with regards to her patients and is very determined to get as many patients as possible into the study...I have doubts around her assessment of global improvement...very gung-ho in an almost non-biased way...I really mistrusted her, and it was very frustrating...I think other people found her exasperating for sure within the company...in terms of senior leadership, I think they felt their hands were bound...she was the primary, the most prolific enroller. — Ex-senior Soleno employee #2, oversight of clinical trial program"

"These expenses relate to the settlement of transaction-related costs of the targets that were outside the regular course of business for our recent acquisitions of ShopKeep and Upserve that were assumed as liabilities on the respective acquisition dates. Lightspeed retained amounts in respect of these liabilities on the closing of each transaction that would otherwise have been paid to the sellers in the transactions. These amounts were not reflected in the net loss of Lightspeed given that they were already taken as expenses by the acquired companies prior to the closing of the respective transactions. — Lightspeed's financials"

"“…we’re not at all surprised that value-oriented investors have taken a significant stake…with Box spending ~41% of revenue on sales and marketing (higher than most SaaS peers in the ~30% range), we think a shift towards margin expansion could provide an avenue for unlocking shareholder value.” — Raymond James, September 2019; “Margin profile is unfit for BOX’s current growth rate. With S&M at north of 40% of revenue, we should be seeing a greater impact in revenue and billings acceleration. Gross margin also continues to decline, coming in at 71.3% this quarter, in comparison to 72.3% last quarter.” — Craig-Hallum, August 2019"

"We appreciate and are humbled by the support our slate received from our fellow shareholders, Dye & Durham employees and leading proxy advisory firms. We do not take this edict lightly and are committed to delivering on the promises we made. We also want to thank the outgoing directors for their professionalism and assistance in effectuating a smooth transition in the best interests of all stakeholders. Looking ahead, we are excited to work with the Company's employees to better serve our customers, improve the Company's culture and create enduring value for shareholders. — Arnaud Ajdler, Founder and Portfolio Manager of Engine"

""ADP. Automatic. The irony of what ADP is doing is often keying data in manually… That’s essentially what many of these people [in implementation] are doing." — Former VP, Business Transformation; "There [were] probably 7 or 8 completely different implementation organizations [within Enterprise]… Implementation was the most inefficient part of National Accounts." — Former Senior Director of Business Transformation at ADP; "[The] service and implementation organization were never touched – [that's] where most of the bodies are – there's basically no leverage across the organization in these functions." — Former Executive Officer"

"“The whole Ferment Consortium, this $300 million slush fund to start child companies of Ginkgo, I would say for sure Ginkgo controls all of those almost certainly...Ferment is basically Viking plus a few other investors. It's a way for Ginkgo to - in an ideal world, people will just pay Ginkgo a fair market rate for their services. Ginkgo can't get enough business to support their valuation just inside their boundary. So, they have this slush fund, that they can basically use to invest in companies, to start companies, and in some cases, it's a small company that has raised very little capital.” — Former director-level employee"

"“Leading questions are one area of patient manipulation. I’ve caught reps specifically telling patients what they have to say. It’s an incentive-based thing for reps. Reps are very very incentivized to want the permanent implant and they’ll tell patients what to say. The rep will ask, what's your pain relief? A patient comes in and their pain is an eight, and after the trial implant the patients says well now it's a five. The rep says, if you want this device you'll have to say you have 50% pain relief, and you want the device right? And the patients says, "Well I guess so, I mean, it helped me a little bit."” — High volume KOL"

""I think they have good lawyers working for them," says David Lipkus, a lawyer specializing in anti-counterfeit in Toronto, who has helped clients sue businesses in Canada selling knock-offs. "Often retailers make mistakes and end up selling fakes." Many lawsuits are settled privately, but the store has been sued by Nike, for selling counterfeit footwear emblazoned with Nike's iconic basketball player silhouette, and by Umbra, a home decoration company, for selling a style of waste basket. In February 2017, Dixon Ticonderoga launched a suit against the dollar store chain for a pencil it's been selling since 2002. — David Lipkus"

"We are very pleased by the quality of the preliminary data from our First-In-Human Feasibility Study conducted in Italy and presented at the American Thyroid Association 2024 Annual Meeting. The data presented on 30 patients in three distinct cohorts demonstrated our system's effectiveness in reducing nodule size. In Cohort 3, three patients received complete nodule treatment and achieved on average 83% volume reduction at one year and significant reductions in symptoms just one month after treatment without evidence of residual fibrosis or scarring that would routinely accompany radiofrequency ablation. — Pulse Biosciences CEO"

""So we've got some new products in the assortment, Alani Nu, GHOST and C4 are all performing very well, and those are newer entrants into the assortment. Red Bull and Monster on the flip side have been stalwarts in the category and continue to grow at an accelerated pace." — CEO of Casey's General Stores, Dec 10, 2024; "And when you look at the small stores and the smaller convenience stores, it's a crapshoot how much of those numbers go into Nielsen." — Monster Co-CEO Schlosberg, Jan 16, 2024; "Last I was there, convenience was doing about 50% of the total gross volume in the market." — Former Monster National Account Manager"

""Let's start with ERP first. First of all, ERP is a 4-year program. We've committed $400 million to this program. We are replacing over 40 separate ERP systems with one global SAP system." — CFO Boehnlein, BaML Conf, May 15, 2018. "You do not go from 42 to 1 ERP system without spending a lot up front, particularly if you want to ensure that the businesses are able to continue to perform." — Katherine Owen, DB Conf, May 8, 2018. "And as you know, it becomes a bit more complicated to do deals and you have other variables coming in there, but we're fully committed to delivering." — Former COO Tim Scannell, MS Conf, Sept 12, 2018."

"“That’s consistent with what I hear from my other colleagues. As we’re all recruiting for more surgeons, any time that someone at TransMedics applies, I automatically just say no. I had a surgeon we had to let go because of quality issues. TransMedics hired him right up. And so, I also have concerns related to the quality of - and not just their hiring practices but what is their training? What is their ongoing, like continuing medical education? How do they stay abreast of some of the changes that are occurring down the line around new techniques?” — Veteran transplant administrator/executive at Massachusetts General Hospital"

"These expenses relate to the settlement of transaction-related costs of the targets that were outside the regular course of business for our recent acquisitions of ShopKeep and Upserve that were assumed as liabilities on the respective acquisition dates. Lightspeed retained amounts in respect of these liabilities on the closing of each transaction that would otherwise have been paid to the sellers in the transactions. These amounts were not reflected in the net loss of Lightspeed given that they were already taken as expenses by the acquired companies prior to the closing of the respective transactions. — Q3 2021 Press Release"

"Southwest has lost the passion for low-cost, low-fare air travel. — Ryanair CEO Michael O'Leary, March 2024; Costs are the real glaring issue at Southwest as they over-hired (23% more headcount vs. '19) during the recovery phase and have seen productivity decline (capacity is up 13.8% vs. '19)... — Melius, January 2024; Southwest is tied (with United) for the most growth, but its unit cost inflation is still worse than all others. — J.P. Morgan, July 2023; When [CEO Bob Jordan] came to the SWAPA Board of Directors meeting, he said specifically that operations wasn't his strong suit. — SWAPA President Casey Murray, August 2022"

""[The City of Seattle case study] is my falsification. So they did buy a lot, but are they seeing a 20% improvement... No, hell no, they're not, it's a blatant lie. If I had access to the XL Link, it'd be the easiest thing in the world to prove otherwise... they're not getting any improvement on these things. [Seattle's fleet manager] will not buy another vehicle from us... you think adding an extra 800 pounds to an already weighed-down ambulance is really going to increase MPG?.. You add a bigger battery onto an overweighted chassis, it's going to bog the thing down, make it even slower and even worse MPG." — Former Employee"

"In each case, the misrecorded item was due to errors as a result of data migration and system configuration arising from our new European business structure during our ERP system conversion in Europe in April 2017. Our review controls and our user acceptance testing controls were not sufficiently designed to identify these items on a timely basis. Though there was no impact on the financial statements for the nine-month period ended September 30, 2017, we concluded that our disclosure controls and procedures were ineffective as of September 30, 2017 and that this deficiency constituted a material weakness. — Source: 2017 10-K"

""The Dubai assets were contributed with no debt attached to them. Some of the assets are in various stages of development, where the progress payments would be required in the next couple of months." — Mindee Lee, CPI PG Director of Corporate Strategy. "In general, these are luxury residential properties in Dubai. And I think if you read any article covering Dubai real estate, you would see this is the hottest segment of the market. We’ve already had a lot of good traction on selling the assets. And as I said earlier, our goal is to sell these properties as soon as possible and move on from it." — David Greenbaum, CPI PG CEO."

"Southwest has lost the passion for low-cost, low-fare air travel. — Ryanair CEO Michael O'Leary, March 2024; Costs are the real glaring issue at Southwest as they over-hired (23% more headcount vs. '19) during the recovery phase and have seen productivity decline (capacity is up 13.8% vs. '19)... — Melius, January 2024; Southwest is tied (with United) for the most growth, but its unit cost inflation is still worse than all others. — J.P. Morgan, July 2023; When [CEO Bob Jordan] came to the SWAPA Board of Directors meeting, he said specifically that operations wasn’t his strong suit. — SWAPA President Casey Murray, August 2022"

"For our group because half of us trained at CHOP, we use a lot of diazoxide, and I even asked that question like, can you just use your garden variety diazoxide. And then, they explain it's extended-release. And okay, but you can give it a couple of times a day.. And, obviously, we still don't know exactly why it works...everybody in endocrine is really familiar with diazoxide for hyperinsulinism. So, trying to understand the difference of mechanism with the long-acting and the salt formulation were some of our questions — Pediatric endocrinologist at a Delaware academic center with eight endocrinologists and ~50 PWS patients"

""The Zenflow procedure is a patient-friendly BPH treatment option that eliminates the need to pierce, ablate, or remove prostatic tissue. Based on favorable initial clinical trial results, it has the promise of becoming a first-line therapy of choice." — Dr. Dean Elterman. "So there are two threats [to Aquablation]...The other threats would be, well, what if you have an office-based procedure that works? And there are two that work a little better. One is called Butterfly stent... So Zenflow is Zenflow is going to win hands down because it is a flexible scope." — Spruce Point Interview with Major Hospital Urologist, Nov 2024"

"“I don't know if Volkswagen have as much transparency into what's going on in there. I don't think people questioned it, to be honest. They were very limited in getting access. It was a very controlled environment. I don't think they got the full picture. I'm pretty sure they didn't.” — Former employee; “Jagdeep and Howard Lukens [Chief Sales Officer] essentially broke down the VW organization and figured out where all the decisions were made, and allocated a guy from Quantumscape to each of these key points. They just had it nailed. Everything was scripted down to practicing everything after the introduction.” — Ex-employee"

"I think all ion traps are about 1000 times slower than superconducting quantum computers... If it takes a day on a superconducting quantum computer to simulate some protein, if all else being equal, which is the caveat, if you did that on a trapped ion computer running 1000 times slower, that's 1000 days, that's three years. And so, great, it's not the age of the universe, quantum computing works, but it's not very practical from a human time scale to wait three years for an answer. They know this, so they're trying to make their processors faster. — Leading quantum computing scientist and longtime friend of both co-founders"

""The purpose of these actions is to have the management of the company carry out their management duties with more consideration of cost of capital and profitability based on the balance sheet, rather than just sales and profit levels on the income statement, in order to achieve sustainable growth and increase corporate value over the mid- to long-term." ... "the management team is expected to take the lead in appropriately allocating resources with sufficient consideration of cost of capital and profitability..." — Action to Implement Management That Is Conscious of Cost of Capital and Stock Price – JPX Tokyo Stock Exchange"

"“...we remain committed to the proactive and disciplined allocation of capital. We have the capacity to return the majority of normalized free cash flow to shareholders in fiscal 2019, subject to factors such as M&A, financial markets and prevailing industry conditions. I am pleased to say this includes a proposed increase in the quarterly cash dividend for the sixth consecutive year, subject to shareholder approval in the annual general meeting in January 2019. Additionally, we retain the optionality to execute on M&A strategically for long-term goals, possibly utilizing debt where appropriate.” — Shuky Sheffer, CEO, Amdocs"

"“That [fuel] cost is completely made up from their rear end.” — Former NRC Commissioner; “I don't want to slam them, I mean I know these people, they did their best, but I think at the end of the day I think when you get to the top... it was as you said - they were goal-seeking [costs]...otherwise it's not viable at all. If they put real numbers of today in there this program would be over.” — Former nuclear fuel cycle expert, International Atomic Energy Agency; “I can't see a scenario where they get to $7,000 / kg and I've been making fuel for 45 years.” — Former Managing Director, Westinghouse Electric - UK Fuel Operations"

""I'm getting ready to hire somebody that's Korean for the US, because that's a huge opportunity for us. But, again, it has to be -- have been a distributor, starts it right, because we can't. We can hire all the Koreans and -- but if -- there's not a distributor out there that's really taking the business. But, definitely, I mean when we think about Korea, I mean, Korea is one of the top countries for Herbalife and Los Angeles has a huge Korean population, San Francisco, New York, so, we're targeting that." -- Ibi Fleming, SVP and Managing Director, North America, Barclays Capital Retail and Restaurants Conference, 4/24/2012"

""This company is very unethical and they do everything they can to try to get over on senior citizens by harassing them to buy this portable oxygen concentrator for $3000 to $5000 and most of these people see the crooked advertisement saying the machine is covered by Medicare." — Former Employee (August 16, 2018); "I would just say that it seems the company is overly obsessed with pumping up their stock price and being considered a ‘hyper growth’ company." — Current Employee (January 9, 2019); "The call objective is to switch from what consumer has seen in advertisement to CASH purchase" — Current Employee (October 18, 2017)"

""The decrease in revenues for the nine months ended October 2, 2020, as compared to the nine months ended September 27, 2019, was primarily attributable to approximately $96 million related to timing of program execution due to COVID-19, a $73 million impact from the sale of our health staff augmentation business in the third quarter of fiscal 2019 and the completion of certain contracts. This was partially offset by a net increase in volumes on certain programs, program wins and a $23 million impact from our acquisition of IMX Medical Management Services, Inc. ("IMX") in the third quarter of fiscal 2019" — Q3 2020 10-Q p.34"

"They're not, and, in my opinion, when a medicine like this first comes out, all the narcolepsy specialists gravitate to it. We like to try things. I think they probably have gotten the large majority of narcolepsy specialists out there, and I don't see them all of a sudden running into huge practices and taking over for—I don't see that happening. I have a feeling it's kind of saturated from that angle...I think most of the prescribers that are going to get on board are going to be these types of prescribers that are like onesies, twosies, threes—they're not going to be high-volume ones. — Sleep physician in the Bay Area, CA"

"“We are a current customer of their A150 series. We use that for our 5-nanometer wafers. We purchased their tool in 2021, I believe. So, we’ve been using it for a couple of years now, and I’m, as well, familiar with their new A300 series.. We only have one of these that we own, and then we’re leasing two ...In some cases, we buy the machines ourselves, and in other cases, we’re leasing capacity.” — Senior employee at Marvell Technology; “They echoed the same problems that we were seeing. ASML customers were also reporting the same things with Lasertec with respect to the light source.” — Senior employee at Marvell Technology"

"“For instance, and it’s just one of many examples, these ion chains break up because of some collisions with a particle that’s in the vacuum chamber, there are some residual particles in there, so those particles can sometimes collide with these ion chains, and it will shatter the chain, in which case, you have to reload the chain and then settle the chain down and make sure all of the calibrations that are done routinely and rather fast to ensure that the computer in a sense comes back to the operational mode. And then, once it’s back to the operational mode, we resume our jobs.” — Former senior scientific employee of IonQ"

""We can absolutely do scrip deals out of the DLC... We can buy from the DLC, we can buy from the Plc, from the Ltd, we can do a lot. That is absolutely not an excuse for M&A, but M&A, of course, has to make sense in itself." — Jakob Stausholm, CEO, 31 July 2024; "I must say we didn't discuss that much because it just adds a layer of complexity... It's not going to make a material difference from our point of view. When we became clear about that, the perfect match for us was to get into Arcadium, we focused in on a cash deal... and therefore didn't choose to open up for further complexity." — Jakob Stausholm, 9 October 2024"

""If they don't have a [detailed] timeline on the electric, that would concern me... The big challenge with upfitted vehicles is you're taking a manufactured vehicle and then changing it. If it takes Ford this long, how long is it going to take a smaller company?" — Former XL Employee E; "The plug-in hybrid alone was $25,000 with 100 mi of battery range. The cost of an all-electric vehicle is double that, at least." — Former XL Employee E; "My guess is that all those upfitters that XL are using now wouldn't be prepared to do all of that. They'd have to come up with a new supply chain to get that done." — Former XL Employee B"

"Oct 28, 2021: "And so as a result, we have seen some increased costs as well in terms of inflation on those items. But to date, our supply chain and procurement teams have really just been able to manage that." — Stryker CFO/IR. Jan 27, 2022: "we expect gross margin performance to be negatively impacted by 50 to 100 basis points with a more pronounced impact in the first half of the year." — Stryker CFO/IR. March 11, 2022: "it's going to lean more towards 100 basis points in the first half of the year and then it will moderate down as some of these supply chain issues improve in the back half of the year." — Stryker CFO/IR."

"“I’ll be frank and say I saw the top-line data, and I did not find it compelling. And that’s why I left the company. We could not meet the primary endpoint... What I saw was not very compelling, either on hyperphagia level, overall significant clinical improvement, or — we had DEXA data...it’s just not very compelling...and then if you combine that with a drug that has a side effect profile that is not fantastic, then what are you really hoping to accomplish? And these patients are on a lot of polypharmacy... the data, overall, I think it’s just not that exciting.” — Ex-Soleno employee #2, key role in clinical trial program"